Key Highlights

  • Omeros (NASDAQ:OMER) reported third-quarter net product sales of USD 35.9 million from YARTEMLEA, up 26.0% from the second quarter, with no sales in the prior-year period.
  • Income from operations was USD 4.5 million, compared with an operating loss of USD 26.4 million a year earlier.
  • The net loss was USD 57.4 million, or USD 0.79 per share, driven by a USD 62.0 million non-cash loss on the Fair Value of convertible note features.
  • Cash, cash equivalents and short-term investments were USD 95.3 million, and nine-month Operating Cash Flow was positive USD 2.9 million.

YARTEMLEA Launch Lifts the Company to an Operating Profit

Omeros (NASDAQ:OMER) filed its Quarterly Report on November 16, 2026. Omeros is a commercial-stage biotechnology company whose only marketed product, YARTEMLEA (narsoplimab-wuug), was approved by the FDA on December 23, 2025 for transplant-associated thrombotic microangiopathy and went on sale in January 2026. Third-quarter net sales were USD 35.9 million, up USD 7.4 million from the second quarter, after gross-to-net deductions of about 14.0%. Cost of product sales was only USD 0.8 million because some inventory was expensed before approval. Operating Income reached USD 4.5 million against a loss of USD 26.4 million a year earlier.

A USD 62.0 Million Derivative Loss Drives the Net Result

Research and development expense was flat at USD 16.1 million, while selling, general and administrative expense rose to USD 14.5 million from USD 10.4 million. Below the operating line, a non-cash loss of USD 62.0 million from marking the conversion option in the 2029 convertible notes to market pushed the quarter to a net loss of USD 57.4 million, or USD 0.79 per share. A loss of USD 1.9 million on early extinguishment of notes was also booked. For nine months, Net Income was USD 11.9 million, or USD 0.16 per share, against a loss of USD 89.8 million, helped by a USD 22.6 million non-cash derivative gain and USD 74.4 million of product sales. The filing notes that stock price swings strongly affect the derivative valuation.

Debt Paydown, Buybacks and a Cash Balance of USD 95.3 Million

Cash, cash equivalents and short-term investments stood at USD 95.3 million at September 30, 2026. Operating cash flow was USD 13.3 million in the quarter and USD 2.9 million for nine months, compared with an outflow of USD 76.3 million a year earlier. In July 2026 the company repurchased USD 30.5 million of 2029 notes for USD 60.2 million, leaving about USD 40.3 million outstanding and cutting potential conversion shares from about 11.4 million to 6.5 million. It also bought back 0.8 million shares for USD 9.9 million. Management expects to fund more than 12 months of operations from existing cash and product sales, and 74,463,571 shares were outstanding on November 11, 2026. The company also sold zaltenibart to Novo Nordisk in November 2025 for USD 240.0 million upfront, and management expects interest and other income to be higher in the fourth quarter as inventory transfers to Novo.

Where Things Stand

The operating Business improved sharply, but accounting for the convertible notes dominated the net result. Omeros (NASDAQ:OMER) earned USD 4.5 million from operations on USD 35.9 million of YARTEMLEA sales, yet a USD 62.0 million non-cash derivative loss produced a USD 57.4 million net loss. Cash of USD 95.3 million and reduced convertible Debt strengthen the balance sheet. The next reports should show whether sales growth continues from the 26.0% quarterly gain and how derivative swings affect results.